^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
etentamig intravenous (ABBV-383 IV)
i
Other names: ABBV-383 IV, TNB-383B, TNB 383B
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
AbbVie
Drug class:
CD3 agonist, BCMA inhibitor
Related drugs:
21d
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=180, Recruiting, AbbVie | Trial completion date: Mar 2027 --> Aug 2029 | Trial primary completion date: Mar 2027 --> Aug 2029
Trial completion date • Trial primary completion date • Adverse events
|
etentamig intravenous (ABBV-383 IV)
1m
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion (clinicaltrials.gov)
P1/2, N=76, Recruiting, AbbVie | Trial primary completion date: Dec 2025 --> Oct 2026
Trial primary completion date • Adverse events
|
etentamig intravenous (ABBV-383 IV)
3ms
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=135, Recruiting, AbbVie | Trial completion date: Jan 2037 --> Mar 2036
Trial completion date • Adverse events
|
iberdomide (CC-220) • etentamig intravenous (ABBV-383 IV)
3ms
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=135, Recruiting, TeneoOne Inc. | Trial primary completion date: Jun 2036 --> Mar 2036
Trial primary completion date • Adverse events
|
iberdomide (CC-220) • etentamig intravenous (ABBV-383 IV)
4ms
A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan (clinicaltrials.gov)
P1, N=8, Active, not recruiting, AbbVie | Trial primary completion date: Sep 2025 --> Mar 2026
Trial primary completion date • Adverse events
|
etentamig intravenous (ABBV-383 IV)
4ms
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=135, Recruiting, TeneoOne Inc. | Not yet recruiting --> Recruiting | Trial completion date: Mar 2036 --> Jan 2037 | Trial primary completion date: Mar 2036 --> Jun 2036
Enrollment open • Trial completion date • Trial primary completion date • Adverse events
|
iberdomide (CC-220) • etentamig intravenous (ABBV-383 IV)
4ms
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (clinicaltrials.gov)
P2/3, N=660, Not yet recruiting, AbbVie
New P2/3 trial • Adverse events
|
lenalidomide • Darzalex (daratumumab) • etentamig intravenous (ABBV-383 IV)
4ms
A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan (clinicaltrials.gov)
P1, N=8, Active, not recruiting, AbbVie | Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Sep 2025
Trial completion date • Trial primary completion date • Adverse events
|
etentamig intravenous (ABBV-383 IV)
8ms
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=135, Not yet recruiting, TeneoOne Inc.
New P1 trial
|
iberdomide (CC-220) • etentamig intravenous (ABBV-383 IV)
11ms
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=320, Recruiting, TeneoOne Inc. | Trial completion date: Jul 2031 --> Sep 2033 | Trial primary completion date: Nov 2028 --> Sep 2033
Trial completion date • Trial primary completion date • Adverse events
|
lenalidomide • Darzalex (daratumumab) • pomalidomide • etentamig intravenous (ABBV-383 IV)
1year
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=180, Recruiting, TeneoOne Inc. | N=120 --> 180 | Trial completion date: Jul 2026 --> Mar 2027 | Trial primary completion date: Jul 2026 --> Mar 2027
Enrollment change • Trial completion date • Trial primary completion date • Adverse events
|
etentamig intravenous (ABBV-383 IV)
over1year
A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused ABBV-383 of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan (clinicaltrials.gov)
P1, N=8, Active, not recruiting, AbbVie | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
Trial completion date • Trial primary completion date • Adverse events
|
etentamig intravenous (ABBV-383 IV)
Share via
